← Oncology Approval Tracker

FDA DECISION ·

Opdivo

nivolumab · Bristol Myers Squibb

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with resectable non-small cell lung cancer measuring at least 4 cm or node positive, without known EGFR mutations or ALK rearrangements; nivolumab plus platinum-doublet chemotherapy before surgery, then nivolumab alone after surgery.

LAMPGEN ANALYSIS

Why it matters

This approval added a postoperative nivolumab phase to the preoperative combination for the defined resectable population.

What research teams should watch

Keep resectability, biomarker exclusions and postsurgical recovery criteria visible to both surgical and medical oncology teams.

PRIMARY RECORDS

Sources